Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been given an average rating of “Moderate Buy” by the sixteen ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $75.67.
Several equities analysts have recently commented on ANAB shares. TD Cowen decreased their price objective on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Wolfe Research reissued an “outperform” rating and issued a $78.00 target price on shares of AnaptysBio in a research report on Monday, August 31st. Leerink Partners decreased their price target on AnaptysBio from $90.00 to $81.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of AnaptysBio in a research report on Tuesday, September 22nd. Finally, HC Wainwright restated a “buy” rating and set a $95.00 target price on shares of AnaptysBio in a report on Tuesday, September 22nd.
Read Our Latest Report on AnaptysBio
Insider Transactions at AnaptysBio
Institutional Investors Weigh In On AnaptysBio
Several large investors have recently added to or reduced their stakes in the business. Irenic Capital Management LP purchased a new stake in AnaptysBio during the second quarter worth approximately $4,755,000. Bank of New York Mellon Corp acquired a new position in AnaptysBio in the second quarter valued at approximately $3,807,000. Squarepoint Ops LLC boosted its holdings in AnaptysBio by 21.2% in the second quarter. Squarepoint Ops LLC now owns 324,446 shares of the biotechnology company’s stock valued at $21,900,000 after purchasing an additional 56,743 shares in the last quarter. Hsbc Holdings PLC purchased a new position in AnaptysBio in the first quarter valued at approximately $7,137,000. Finally, Bank of America Corp DE purchased a new position in AnaptysBio in the second quarter valued at approximately $28,202,000.
AnaptysBio Price Performance
NASDAQ:ANAB opened at $48.77 on Thursday. The company’s 50-day moving average is $50.17 and its two-hundred day moving average is $56.31. AnaptysBio has a 1-year low of $21.93 and a 1-year high of $72.36. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of 9.08 and a beta of 0.70.
AnaptysBio (NASDAQ:ANAB – Get Free Report) last issued its quarterly earnings data on Monday, September 21st. The biotechnology company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $5.57. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. The firm had revenue of $27.49 million for the quarter, compared to analyst estimates of $14.06 million. During the same period in the previous year, the firm earned ($1.30) EPS. As a group, equities analysts anticipate that AnaptysBio will post -1.30 earnings per share for the current fiscal year.
AnaptysBio Company Profile
AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.
Read More
- Five stocks we like better than AnaptysBio
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
